Hiding under the skin: A welcome surprise in psoriasis

[1]  Mayte Suárez-Fariñas,et al.  Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis , 2012, The Journal of investigative dermatology.

[2]  J. Krueger,et al.  Putting together the psoriasis puzzle: an update on developing targeted therapies , 2012, Disease Models & Mechanisms.

[3]  P. Haslett,et al.  IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. , 2012, The Journal of allergy and clinical immunology.

[4]  Subhashis Banerjee,et al.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. , 2012, The New England journal of medicine.

[5]  J. Ortonne,et al.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. , 2012, The New England journal of medicine.

[6]  Ping Chen,et al.  Interleukin-17 contributes to cardiovascular diseases , 2012, Molecular Biology Reports.

[7]  J. Renauld,et al.  IL-22 Is Required for Imiquimod-Induced Psoriasiform Skin Inflammation in Mice , 2011, The Journal of Immunology.

[8]  A. Menter,et al.  Psoriasis: comorbidities and associations. , 2011, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

[9]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[10]  P. Valdez,et al.  Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis , 2007, Nature.

[11]  Lawrence Steinman,et al.  A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage , 2007, Nature Medicine.

[12]  R. Kastelein,et al.  Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain , 2003, Nature.